GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Pietrantonio, Filippo, Berenato, Rosa, Maggi, Claudia, Caporale, Marta, Milione, Massimo, Perrone, Federica, Tamborini, Elena, Baratti, Dario, Kusamura, Shigeki, Mariani, Luigi, Niger, Monica, Mennitto, Alessia, Gloghini, Annunziata, Bossi, Ilaria, Settanni, Giulio, Busico, Adele, Bagnoli, Pietro Francesco, Di Bartolomeo, Maria, Deraco, Marcello, de Braud, Filippo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/
https://ncbi.nlm.nih.gov/pubmed/27154293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados